At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Test-Retest Reproducibility of 18F-AV-1451 Injection for Brain Imaging of Tau in Healthy Volunteers and Cognitively Impaired Subjects.
In Brief
A Phase 1 clinical trial evaluating Flortaucipir F18 and Brain PET scan for Alzheimer's Disease. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers, MCI and AD subjects provide the same results.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionMay 2014
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartNov 13, 2013
Primary CompletionMay 30, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.6 years ago
Interventions
Flortaucipir F18drug
IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
Brain PET scanprocedure
positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection